Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PLN-101095

Small molecule · Inhibitor of integrin alpha-V beta-1 and integrin alpha-V beta-8 · developed by Pliant Therapeutics

Phase 1 Most advanced trial
PLRX Developer
1 Registered trials

What is PLN-101095?

PLN-101095 is an orally bioavailable small molecule that dually inhibits integrins alpha-V beta-1 and alpha-V beta-8 in the tumor microenvironment. By blocking these integrins it prevents activation of TGF-beta, which is studied in advanced or metastatic solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
integrin alpha-V beta-1, integrin alpha-V beta-8
Mechanism
Inhibitor of integrin alpha-V beta-1 and integrin alpha-V beta-8
Pathways
TGF-beta activation, T-cell infiltration, checkpoint inhibitor resistance
Therapy area
Oncology
Developer
Pliant Therapeutics, Inc. (PLRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06270706 Phase 1 Advanced or Metastatic Solid Tumor Recruiting PLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic Solid Tumor

More from Pliant Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PLRX page.

Follow PLRX, the company behind PLN-101095

See PLRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PLRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.